Form 4: Arcellx CMO Sells Shares via Pre-Arranged 10b5-1 Plan

Arcellx Chief Medical Officer Christopher Heery reported the sale of 73 common shares for $80.16 each, executed under a Rule 10b5-1 trading plan.

Summary

• Christopher Heery, Chief Medical Officer of Arcellx, Inc. (ACLX), reported a transaction involving the company's common stock.
• The transaction, which occurred on September 29, 2025, was a sale of 73 shares of common stock.
• The shares were sold at a price of $80.16 per share.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was established by Mr. Heery on March 23, 2025.
• Following this reported transaction, Christopher Heery beneficially owns 21,658 shares of Arcellx common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sale is a relatively small amount of shares and was conducted under a pre-arranged 10b5-1 plan, which typically indicates a non-discretionary transaction not based on new material information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and non-discretionary transaction rather than a sale based on new material information.

Negatives

• Chief Medical Officer Christopher Heery sold 73 shares of common stock.

Future Outlook

NA

Industry Context

This filing is an insider transaction report (Form 4), which details changes in beneficial ownership by company insiders. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor change in insider holdings and, given its pre-planned nature, is unlikely to significantly impact shareholder sentiment or the company's valuation.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of a small number of shares by a Chief Medical Officer under a 10b5-1 plan. Such transactions are typically not indicative of new material information or a change in management's outlook on the company's prospects. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Arcellx, ACLX, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Christopher Heery, Chief Medical Officer